Abbott Laboratories (ABT) Shares Sold by Sheaff Brock Investment Advisors LLC

Sheaff Brock Investment Advisors LLC lessened its position in shares of Abbott Laboratories (NYSE:ABT) by 27.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 11,837 shares of the healthcare product maker’s stock after selling 4,381 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Abbott Laboratories were worth $676,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the company. Farmers National Bank raised its position in shares of Abbott Laboratories by 2.4% in the second quarter. Farmers National Bank now owns 3,653 shares of the healthcare product maker’s stock valued at $178,000 after buying an additional 85 shares in the last quarter. L & S Advisors Inc raised its position in shares of Abbott Laboratories by 0.7% in the second quarter. L & S Advisors Inc now owns 21,348 shares of the healthcare product maker’s stock valued at $1,038,000 after buying an additional 150 shares in the last quarter. Moors & Cabot Inc. raised its position in shares of Abbott Laboratories by 0.3% in the second quarter. Moors & Cabot Inc. now owns 48,781 shares of the healthcare product maker’s stock valued at $2,376,000 after buying an additional 161 shares in the last quarter. Regal Investment Advisors LLC raised its position in shares of Abbott Laboratories by 4.3% in the second quarter. Regal Investment Advisors LLC now owns 5,749 shares of the healthcare product maker’s stock valued at $279,000 after buying an additional 238 shares in the last quarter. Finally, Rikoon Group LLC raised its position in shares of Abbott Laboratories by 0.4% in the second quarter. Rikoon Group LLC now owns 61,548 shares of the healthcare product maker’s stock valued at $2,991,000 after buying an additional 275 shares in the last quarter. Institutional investors own 72.37% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of research firms have recently weighed in on ABT. Leerink Swann reiterated a “market perform” rating and issued a $68.00 price target (up from $60.00) on shares of Abbott Laboratories in a research report on Thursday, January 25th. Bank of America lifted their price target on shares of Abbott Laboratories from $60.00 to $70.00 in a research report on Wednesday, January 24th. They noted that the move was a valuation call. BMO Capital Markets lifted their price target on shares of Abbott Laboratories from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Stifel Nicolaus lifted their price target on shares of Abbott Laboratories from $63.00 to $71.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Finally, Barclays boosted their price objective on shares of Abbott Laboratories from $66.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $65.47.

In other Abbott Laboratories news, insider Roger Bird sold 8,262 shares of the business’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $62.75, for a total transaction of $518,440.50. Following the sale, the insider now owns 58,574 shares of the company’s stock, valued at $3,675,518.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Stephen R. Fussell sold 56,401 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $59.61, for a total transaction of $3,362,063.61. Following the sale, the insider now directly owns 184,884 shares in the company, valued at approximately $11,020,935.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 124,261 shares of company stock worth $7,559,987. Insiders own 0.74% of the company’s stock.

NYSE ABT opened at $59.92 on Friday. The firm has a market cap of $104,640.33, a price-to-earnings ratio of 23.97, a P/E/G ratio of 1.78 and a beta of 1.52. Abbott Laboratories has a fifty-two week low of $42.31 and a fifty-two week high of $64.60. The company has a current ratio of 2.26, a quick ratio of 1.86 and a debt-to-equity ratio of 0.87.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The firm had revenue of $7.59 billion for the quarter, compared to analysts’ expectations of $7.38 billion. Abbott Laboratories had a net margin of 1.74% and a return on equity of 13.88%. The company’s revenue was up 42.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.65 earnings per share. sell-side analysts predict that Abbott Laboratories will post 2.86 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be paid a dividend of $0.28 per share. The ex-dividend date is Thursday, April 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.87%. Abbott Laboratories’s payout ratio is presently 44.80%.

COPYRIGHT VIOLATION WARNING: “Abbott Laboratories (ABT) Shares Sold by Sheaff Brock Investment Advisors LLC” was published by WKRB News and is the property of of WKRB News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/04/01/abbott-laboratories-abt-shares-sold-by-sheaff-brock-investment-advisors-llc.html.

Abbott Laboratories Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply